Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : $2,200.0 million
Deal Type : Collaboration
Septerna and Novo Nordisk Partner on Oral Drugs for Obesity and Metabolic Diseases
Details : The companies will initially commence development programs for potential therapies targeting one or more GPCRs to discover and develop oral small-molecule medicines for obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $200.0 million
May 14, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : $2,200.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kallyope Announces License Agreement with Novo Nordisk
Details : Under the terms of the license agreement, Novo Nordisk will discover novel peptide therapeutics including as a potential new mechanism for the treatment of obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Apple Tree Partners
Deal Size : $52.0 million
Deal Type : Series A Financing
Details : The net proceeds will be used for advancing multiple novel small molecule therapeutics focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Apple Tree Partners
Deal Size : $52.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
AstraZeneca Collaborate with Regeneron to Research, Develop & Commercialise
Details : AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 27, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration